Market research
GLMD Galmed Pharmaceuticals Ltd
NASDAQ USD Healthcare
Latest close
Loading market data…
Test a moving-average rule with historical data.
- Market cap
- 4M
- P/E ratio
- Not available
- Analyst target
- 12
- Dividend yield
- Not available
- Beta
- 0.68
Profile
Company facts
- Exchange
- NASDAQ
- Currency
- USD
- Sector
- Healthcare
- Industry
- Biotechnology
- ISIN
- IL0011313900
- Market cap
- 4M
- P/E ratio
- Not available
- Analyst target
- 12
- Dividend yield
- Not available
- Beta
- 0.68
About
About Galmed Pharmaceuticals Ltd
Galmed Pharmaceuticals Ltd., a biopharmaceutical company, focuses on the development of therapeutics for the treatment of liver diseases and related indications. The company develops Aramchol, a first-in-class synthetic fatty acid-bile acid conjugate molecule which is in a Phase III study for oral treatment for non-alcoholic steato-hepatitis (NASH) in patients who are overweight or obese and have prediabetes or type II diabetes mellitus. The company also evaluates Aramchol through the ARRIVE Study, a Phase IIa clinical trial with HIV-associated non-alcoholic fatty liver disease and lipodystrophy. In addition, it engages in the development of Amilo-5MER, a 5 amino acid synthetic peptide methionine, threonine, alanine, aspartic acid, and valine. Further, the company is developing MyBiotics, which is in pre-clinical trials for NASH and fibrosis. It has a license agreement with Samil Pharma. Co., Ltd. for the commercialization of Aramchol in the Republic of Korea; and a collaboration agreement with OnKai for its AI platform and Tissue Dynamics to develop a novel human chronic cardiac fibrosis model. Galmed Pharmaceuticals Ltd. was founded in 2000 and is headquartered in Ramat Gan, Israel.
Visit company websiteCommunity
Investor discussion
1 comment
Sign in to join the GLMD discussion.
5 years, 4 months ago
Galmed Pharmaceuticals Ltd is currently in a long term downtrend where the price is trading 14.7% below its 200 day moving average.
From a valuation standpoint, the stock is 100.0% cheaper than other stocks from the Healthcare sector with a price to sales ratio of 0.0.
Galmed Pharmaceuticals Ltd's total revenue sank by nan% to $0 since the same quarter in the previous year.
Its net income has dropped by 24.0% to $-10M since the same quarter in the previous year.
Finally, its free cash flow fell by 92.9% to $-8M since the same quarter in the previous year.
Based on the above factors, Galmed Pharmaceuticals Ltd gets an overall score of 1/5.